Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 77

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 77
---
 ​ | ​                          |            ​ |
| Common stock (par value $0.0001 per share, 250,000,000 shares authorized at September 30, 2024; 10,014,872 shares issued and outstanding as of September 30, 2024) and 50,014,872 shares, as adjusted                                                                     | ​ | ​                        |        1,002 | ​ | ​                     |        1,002 | ​ | ​                          |        5,001 |
| Additional paid-in capital                                                                                                                                                                                                                                                | ​ | ​                        |  107,049,640 | ​ | ​                     |  107,049,640 | ​ | ​                          |  115,502,641 |
| Accumulated deficit                                                                                                                                                                                                                                                       | ​ | ​                        | -103,934,931 | ​ | ​                     | -109,072,063 | ​ | ​                          | -109,072,063 |
| Total Stockholders’ Equity                                                                                                                                                                                                                                                | ​ | $                        |    3,115,711 | ​ | $                     |   -2,021,421 | ​ | $                          |    6,435,579 |
| Total Capitalization                                                                                                                                                                                                                                                      | ​ | $                        |   20,693,630 | ​ | $                     |   13,556,498 | ​ | $                          |   22,013,498 |

The table above assumes that that the Pre-Funded Warrants issued in this offering are exercised in full. The table above does not give effect to (i) the adjustment to the conversion price of the Company’s Series A Preferred Stock and related warrants as a result of this offering due to the anti-dilution provisions contained in such Series A Preferred Stock and warrants, and (ii) the issuance of the Stock

44

Awards in the amount of 2,200,000 shares of restricted shares of common stock to be issued to certain directors and officers of the Company, subject to the closing of this offering. The table above is based on 10,014,872 shares of our common stock outstanding as of September 30, 2024, and excludes the following:

| ● | 8,188,742 shares of common stock issuable upon exercise of the Company’s outstanding warrants at an average weighted exercise of $14.49 per share; |

| ● | 509,133 shares of common stock underlying outstanding options of the Company, with a weighted average exercise price of